Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs

Olema Pharmaceuticals

16/03/2026 11:11

Overview

US breast cancer drug developer's Q4 net loss widened on higher R&D expenses

Company ended 2025 with $505.4 mln in cash and equivalents after $218.5 mln public offering

Increased R&D spending driven by late-stage trials for palazestrant and advancement of OP-3136

Result Drivers

CLINICAL TRIAL ADVANCEMENT - Increased R&D expenses attributed to late-stage trials for palazestrant and development of OP-3136

INCREASED CORPORATE COSTS - Higher G&A expenses due to increased spending on corporate-related costs

Company press release: ID:nGNX9FCg4N

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$46.06 mln
Q4 Income From Operations
-$50.08 mln
Q4 Operating Expenses
$50.08 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $43.00, about 192.3% above its March 13 closing price of $14.71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)